Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...
Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...
Good Housekeeping UK on MSN23h
Everything you need to know about weightloss drugsWhat about the side-effects? Will I regain all my weight? Dr Sarah Jarvis has the answers to your burning questions.
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
Hosted on MSN16h
AbbVie enters obesity space with $2.3bn Gubra dealAbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...
You've probably heard about the relatively new weight loss medications and the results some people have seen with them and you may have wondered if they could help you.
On World Obesity Day, the public health doctor says while much is changing around drugs and weight loss, we cannot lose sight ...
If obesity is seen not just as a personal struggle but a disease of public health concern, we can look for systemic solutions ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Australian telehealth startup Eucalyptus has made $200 million in 18 months as demand for weight loss drugs soars. Here's how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback